Evaluation of the Vitek 2 AST-N055 Card for the Susceptibility Testing of Acinetobacter baumannii Isolates to Amikacin.
10.5145/KJCM.2009.12.3.144
- Author:
Dong Jin PARK
1
;
Wonkeun SONG
;
Taek Kyung KIM
;
Jae Seok KIM
;
Han Sung KIM
;
Kyu Man LEE
Author Information
1. Department of Laboratory Medicine, Hallym University College of Medicine, Seoul, Korea. swonkeun@hallym.or.kr
- Publication Type:Note
- Keywords:
Amikacin;
Acinetobacter baumannii;
Vitek 2
- MeSH:
Acinetobacter;
Acinetobacter baumannii;
Amikacin
- From:Korean Journal of Clinical Microbiology
2009;12(3):144-145
- CountryRepublic of Korea
- Language:English
-
Abstract:
We collected 76 clinical isolates of Acinetobacter baumannii (amikacin MIC by Vitek 2 AST-N055 card: < or =2microgram/mL, 11 isolates; 4microgram/mL, 19 isolates; 8microgram/ mL, 17 isolates; 16microgram/mL, 27 isolates; and > or =64microgram/ mL, 2 isolates) from a university hospital and evaluated the Vitek 2 AST-N055 card vs the broth microdilution as a reference method for testing susceptibility to amikacin. Vitek 2 AST-N055 card yielded very major errors in 15 isolates (19.7%) and minor errors in 26 isolates (34.2%). Of the 15 isolates shown very major errors, 14 had Vitek 2 MICs ranging from 8 to 16microgram/mL. The results of our study suggest strongly that it is unreliable to test the amikacin susceptibility by Vitek 2 AST-N055 card of A. baumannii with the Vitek 2 MICs ranging from 8 to 16microgram/mL. In those cases, another susceptibility test, such as broth microdilution (BMD), should be performed to confirm the results.
